Fosun Pharma terminates Phase I clinical and follow-up development of SGLT-2 inhibitors

Article source: Medical Rubik's Cube Info

On December 28, Fosun Pharma issued an announcement stating that its subsidiary, Jiangsu Wanbang, had decided to terminate the clinical trial and subsequent development of the SGLT-2 inhibitor vanagliflozin

Vangligliflozin is an SGLT-2 inhibitor introduced by IMC from Sirona Biochem in January 2014 and is intended to be used in the treatment of type II diabetes

As of now, the domestic market SGLT-2 inhibitors include AstraZeneca An Datang ®, Boehringer Ingelheim International Inc.

Since vanagliflozin is still in the phase I clinical trial stage, and many SGLT-2 inhibitors have been launched at home and abroad, the market competition has been relatively fierce, after careful consideration, based on factors such as investment in the subsequent development of the new drug and market value In order to rationally allocate R&D resources and focus on advantageous projects in the R&D pipeline, Jiangsu Wanbang decided to terminate the clinical trial and subsequent development of the new drug